tVNS for clinicians
Why this zone exists
Vagus nerve stimulation is not a new idea. Clinicians have been stimulating the vagus to treat epilepsy and depression since the 1980s, and the physiological rationale stretches back further than that. What is new is the ability to deliver that stimulation transcutaneously, at home, without surgery, and under a Class IIa medical device authorisation.
This zone is for healthcare professionals who want the evidence, the mechanism, and the practical detail behind tVNS, without the lay-language simplifications we use on the public pages. If you are here because a patient has asked you about tVNS, or because you are considering neuromodulation as an adjunct to your existing treatment options, you are in the right place.
What the tVNS device is
The tVNS device is a small pulse generator connected to an ear electrode that sits in the cymba conchae. The cymba conchae is the one region of the outer ear with 100% vagal innervation, via the auricular branch of the vagus nerve. Pulses travel from this branch to the nucleus tractus solitarii in the medulla, and from there to the locus coeruleus, raphe nuclei, thalamus, insula, and anterior cingulate cortex. The device is manufactured by tVNS Technologies GmbH in Germany and distributed in the UK by Anatomical Concepts UK.
It is CE marked as a Class IIa medical device under EU MDR 2017/745. Indications cover epilepsy, depression, chronic migraine, and Prader-Willi syndrome. It is used adjunctively, never as monotherapy. Per the Instructions for Use, the tVNS E delivers a biphasic waveform at 25 Hz (28 s on, 32 s off), titrated to a strong but non-painful paresthesia.
What you will find in this zone
Overview
The mechanism, the anatomy, and the framework for how we think about vagal afferent engagement. Starts with the brainstem relays, works outwards to the cortical projections and the cholinergic anti-inflammatory pathway, and finishes with the practical question: how do we know the stimulus is reaching the intended fibres.
Practice guide
The anchor document for the zone. How to select candidates, how to set stimulation parameters, how to structure a trial, how to decide whether a patient is responding, and how to escalate or de-escalate. Written with the hands-on clinician in mind.
Conditions
Deep clinical pages, one per indication. Each follows the same structure: pathophysiology, evidence base, candidate selection, stimulation parameters, expected time course, and what to watch for. At present, epilepsy is live. Depression, chronic migraine, and Prader-Willi syndrome are in draft.
Browse clinician condition pages
Evidence library
Full references and study summaries. The summaries are honest about the quality of the evidence and the limits of blinding in trials where paresthesia makes sham conditions difficult to design. We do not oversell.
Resources
Downloads and printables. Patient handouts you can give to the people in your clinic, protocol templates you can adapt, and practical guides on related topics such as HRV metrics in rehabilitation.
Book a demo or ask a question
If you want to see the device in person, try it on your own ear, or talk through a specific case, we are happy to arrange a call or visit. The UK support is run directly by Anatomical Concepts UK, not routed through the manufacturer, so you get a direct answer from someone who has worked in rehabilitation technology for over thirty years.
A note on the evidence
The tVNS literature has strengths and weaknesses that are worth knowing up front. The strengths: a clear physiological rationale, consistent findings across several condition areas, and a favourable safety profile in which the reported adverse events are predominantly local, mild, and transient. The weaknesses: heterogeneous stimulation parameters between studies, compromised blinding in trials where sham conditions do not reliably replicate paresthesia, and a shortage of pre-registered protocols in some of the older literature.
We think the honest framing is this. tVNS is a credible adjunctive neuromodulation tool with a good safety profile and a growing evidence base. It is not a first line treatment. It is not a guarantee. It is a genuine option worth considering for patients who are not responding well enough to conventional care and for whom the alternatives are either surgical or unsatisfactory.
If that framing matches how you think about treatment decisions, the rest of this zone is for you.
tVNS is a Class IIa medical device manufactured by tVNS Technologies GmbH, Germany. Distributed in the UK by Anatomical Concepts UK Ltd.